International Journal of Cancer Management

Published by: Kowsar
Uncorrected Proof scheduled for 12 (4)

Characterization of Novel Non-Synonymous Genomic Variants Altering Drug Response of DNA Topoisomerase II Alpha

Farzaneh Mohamadi Farsani 1 , Sadeq Vallian 1 , * , Mohamad Reza Ganjalikhany 1 and Nadia Pourmoshir 1
Authors Information
1 Department of Biology, Faculty of Sciences, University of Isfahan, Isfahan, Iran
Article information
  • International Journal of Cancer Management: In Press (In Press); e66993
  • Published Online: April 17, 2019
  • Article Type: Research Article
  • Received: February 1, 2018
  • Revised: February 27, 2019
  • Accepted: April 10, 2019
  • DOI: 10.5812/ijcm.66993

To Cite: Mohamadi Farsani F, Vallian S, Ganjalikhany M R , Pourmoshir N . Characterization of Novel Non-Synonymous Genomic Variants Altering Drug Response of DNA Topoisomerase II Alpha, Int J Cancer Manag. Online ahead of Print ; In Press(In Press):e66993. doi: 10.5812/ijcm.66993.

Abstract
Copyright © 2019, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Methods
3. Results
4. Discussion
Footnotes
References
  • 1. Cargill M, Altshuler D, Ireland J, Sklar P, Ardlie K, Patil N, et al. Characterization of single-nucleotide polymorphisms in coding regions of human genes. Nat Genet. 1999;22(3):231-8. doi: 10.1038/10290. [PubMed: 10391209].
  • 2. Chasman D, Adams RM. Predicting the functional consequences of non-synonymous single nucleotide polymorphisms: Structure-based assessment of amino acid variation. J Mol Biol. 2001;307(2):683-706. doi: 10.1006/jmbi.2001.4510. [PubMed: 11254390].
  • 3. Yates CM, Sternberg MJ. The effects of non-synonymous single nucleotide polymorphisms (nsSNPs) on protein-protein interactions. J Mol Biol. 2013;425(21):3949-63. doi: 10.1016/j.jmb.2013.07.012. [PubMed: 23867278].
  • 4. Kwok CJ, Martin AC, Au SW, Lam VM. G6PDdb, an integrated database of glucose-6-phosphate dehydrogenase (G6PD) mutations. Hum Mutat. 2002;19(3):217-24. doi: 10.1002/humu.10036. [PubMed: 11857737].
  • 5. Livingston RJ, von Niederhausern A, Jegga AG, Crawford DC, Carlson CS, Rieder MJ, et al. Pattern of sequence variation across 213 environmental response genes. Genome Res. 2004;14(10A):1821-31. doi: 10.1101/gr.2730004. [PubMed: 15364900]. [PubMed Central: PMC524406].
  • 6. Erriquez J, Becco P, Olivero M, Ponzone R, Maggiorotto F, Ferrero A, et al. TOP2A gene copy gain predicts response of epithelial ovarian cancers to pegylated liposomal doxorubicin: TOP2A as marker of response to PLD in ovarian cancer. Gynecol Oncol. 2015;138(3):627-33. doi: 10.1016/j.ygyno.2015.06.025. [PubMed: 26100858].
  • 7. Bugg BY, Danks MK, Beck WT, Suttle DP. Expression of a mutant DNA topoisomerase II in CCRF-CEM human leukemic cells selected for resistance to teniposide. Proc Natl Acad Sci U S A. 1991;88(17):7654-8. doi: 10.1073/pnas.88.17.7654. [PubMed: 1652758]. [PubMed Central: PMC52360].
  • 8. Hinds M, Deisseroth K, Mayes J, Altschuler E, Jansen R, Ledley FD, et al. Identification of a point mutation in the topoisomerase II gene from a human leukemia cell line containing an amsacrine-resistant form of topoisomerase II. Cancer Res. 1991;51(17):4729-31. [PubMed: 1651812].
  • 9. Patel S, Fisher LM. Novel selection and genetic characterisation of an etoposide-resistant human leukaemic CCRF-CEM cell line. Br J Cancer. 1993;67(3):456-63. doi: 10.1038/bjc.1993.87. [PubMed: 8382508]. [PubMed Central: PMC1968246].
  • 10. Danks MK, Warmoth MR, Friche E, Granzen B, Bugg BY, Harker WG, et al. Single-strand conformational polymorphism analysis of the M(r) 170,000 isozyme of DNA topoisomerase II in human tumor cells. Cancer Res. 1993;53(6):1373-9. [PubMed: 8383009].
  • 11. Farsani FM, Ganjalikhany MR, Vallian S. Studies on non-synonymous polymorphisms altering human DNA topoisomerase II-alpha interaction with amsacrine and mitoxantrone: An in silico approach. Curr Cancer Drug Targets. 2017;17(7):657-68. doi: 10.2174/1568009617666161109142629. [PubMed: 27834128].
  • 12. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988;16(3):1215. doi: 10.1093/nar/16.3.1215. [PubMed: 3344216]. [PubMed Central: PMC334765].
  • 13. Sherry ST, Ward MH, Kholodov M, Baker J, Phan L, Smigielski EM, et al. dbSNP: The NCBI database of genetic variation. Nucleic Acids Res. 2001;29(1):308-11. doi: 10.1093/nar/29.1.308. [PubMed: 11125122]. [PubMed Central: PMC29783].
  • 14. Little S. Amplification-refractory mutation system (ARMS) analysis of point mutations. Curr Protoc Hum Genet. 2001;Chapter 9:Unit 9 8. doi: 10.1002/0471142905.hg0908s07. [PubMed: 18428319].
  • 15. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, et al. PLINK: A tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet. 2007;81(3):559-75. doi: 10.1086/519795. [PubMed: 17701901]. [PubMed Central: PMC1950838].
  • 16. Nagy S, Poczai P, Cernak I, Gorji AM, Hegedus G, Taller J. PICcalc: An online program to calculate polymorphic information content for molecular genetic studies. Biochem Genet. 2012;50(9-10):670-2. doi: 10.1007/s10528-012-9509-1. [PubMed: 22573137].
  • 17. Ramensky V, Bork P, Sunyaev S. Human non-synonymous SNPs: Server and survey. Nucleic Acids Res. 2002;30(17):3894-900. doi: 10.1093/nar/gkf493. [PubMed: 12202775]. [PubMed Central: PMC137415].
  • 18. Carlson B. SNPs-A shortcut to personalized medicine. Genet Eng Biotechnol New. 2008;28(12):12.
  • 19. Fredman D, Sawyer SL, Stromqvist L, Mottagui-Tabar S, Kidd KK, Wahlestedt C, et al. Nonsynonymous SNPs: Validation characteristics, derived allele frequency patterns, and suggestive evidence for natural selection. Hum Mutat. 2006;27(2):173-86. doi: 10.1002/humu.20289. [PubMed: 16429399].
  • 20. Nitiss JL. Targeting DNA topoisomerase II in cancer chemotherapy. Nat Rev Cancer. 2009;9(5):338-50. doi: 10.1038/nrc2607. [PubMed: 19377506]. [PubMed Central: PMC2748742].
  • 21. Lipshultz SE, Scully RE, Lipsitz SR, Sallan SE, Silverman LB, Miller TL, et al. Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: Long-term follow-up of a prospective, randomised, multicentre trial. Lancet Oncol. 2010;11(10):950-61. doi: 10.1016/S1470-2045(10)70204-7. [PubMed: 20850381]. [PubMed Central: PMC3756093].
  • 22. Vrooman LM, Neuberg DS, Stevenson KE, Asselin BL, Athale UH, Clavell L, et al. The low incidence of secondary acute myelogenous leukaemia in children and adolescents treated with dexrazoxane for acute lymphoblastic leukaemia: A report from the Dana-Farber Cancer Institute ALL Consortium. Eur J Cancer. 2011;47(9):1373-9. doi: 10.1016/j.ejca.2011.03.022. [PubMed: 21514146]. [PubMed Central: PMC3736806].
  • 23. Alwi ZB. The Use of SNPs in Pharmacogenomics Studies. Malays J Med Sci. 2005;12(2):4-12. [PubMed: 22605952]. [PubMed Central: PMC3349395].
  • 24. Liu BH. Statistical genomics: linkage, mapping, and QTL analysis. CRC press; 1997.
  • 25. Guo X, Elston RC. Linkage information content of polymorphic genetic markers. Hum Hered. 1999;49(2):112-8. doi: 10.1159/000022855. [PubMed: 10077733].

Featured Image:

Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments